Literature DB >> 9216839

Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.

H S Ahn1, A Bercovici, G Boykow, A Bronnenkant, S Chackalamannil, J Chow, R Cleven, J Cook, M Czarniecki, C Domalski, A Fawzi, M Green, A Gündes, G Ho, M Laudicina, N Lindo, K Ma, M Manna, B McKittrick, B Mirzai, T Nechuta, B Neustadt, C Puchalski, K Pula, H Zhang.   

Abstract

Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9216839     DOI: 10.1021/jm9608467

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.

Authors:  Nam-Jun Kim; Jung-Hwan Baek; JinAh Lee; HyeNa Kim; Jun-Kyu Song; Kyung-Hee Chun
Journal:  Exp Mol Med       Date:  2019-01-11       Impact factor: 8.718

3.  Regulation of cAMP accumulation and activity by distinct phosphodiesterase subtypes in INS-1 cells and human pancreatic β-cells.

Authors:  Evan P S Pratt; Kyle E Harvey; Amy E Salyer; Gregory H Hockerman
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

4.  Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblasts.

Authors:  Lukas Menges; Christian Krawutschke; Ernst-Martin Füchtbauer; Annette Füchtbauer; Peter Sandner; Doris Koesling; Michael Russwurm
Journal:  Br J Pharmacol       Date:  2019-12-27       Impact factor: 8.739

5.  The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Vahri Beaumont; Larry Park; Arash Rassoulpour; Ulrike Dijkman; Taneli Heikkinen; Kimmo Lehtimaki; Outi Kontkanen; Rand Al Nackkash; Gillian P Bates; Melanie Gleyzes; Esther Steidl; Sylvie Ramboz; Carol Murphy; Maria G Beconi; Celia Dominguez; Ignacio Munoz-Sanjuan
Journal:  PLoS Curr       Date:  2014-02-13

6.  An EPAC1/PDE1C-Signaling Axis Regulates Formation of Leading-Edge Protrusion in Polarized Human Arterial Vascular Smooth Muscle Cells.

Authors:  Paulina Brzezinska; Donald H Maurice
Journal:  Cells       Date:  2019-11-20       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.